Form 4: Gossamer Bio Director Skye Drynan Acquires 230,000 Stock Options
SEC Form 4 Filing
Director Skye Drynan acquired 230,000 stock options in Gossamer Bio, Inc. on March 11, 2024, at an exercise price of $1.34.
Summary
- On March 11, 2024, Skye Drynan, a director of Gossamer Bio, Inc., acquired 230,000 stock options.
- The exercise price of these options is $1.34.
- The options vest monthly over three years, contingent upon continuous service to the corporation.
- The expiration date for these options is March 10, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options to a director could potentially align their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of transaction: Skye Drynan acquired 230,000 stock options. |
| 03/12/2024 | Date of signature on the Form 4 filing. |
| 03/10/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.